Mirati Therapeutics Inc (MRTX) 22.51 $MRTX
InsiderInsights.com Daily Round Up 2/5/15: RRC, MRTX, CG, PH
InsiderInsights - at Seeking Alpha - Fri Feb 06, 9:00AM CST
NLSN: 45.59 (+2.02), ATLS: 30.17 (+0.27), JBHT: 82.88 (+1.09), NOC: 167.14 (-0.15), PMBC: 7.20 (+0.10), AMGN: 153.48 (+0.30), MPWR: 50.32 (+0.16), SSD: 35.51 (-0.09), RRC: 50.84 (+0.07), CG: 28.18 (+0.04), WIW: 11.29 (unch), ULTI: 163.76 (+1.60), PH: 124.06 (+2.23), ONCE: 46.25 (+0.07), RWC: 5.82 (+0.06), CDNA: 6.30 (-0.14), MRTX: 22.51 (-0.08), MSFT: 43.87 (+0.78), TCON: 9.34 (-0.16), MA: 87.14 (-0.38)
5 Stocks Insiders Love Right Now: Microsoft, Alnylam and More
at The Street - Wed Feb 04, 9:02AM CST
Insiders at these companies have been scooping up shares of their own stock lately.
ALNY: 95.54 (+1.67), ALB: 54.59 (+0.63), MRTX: 22.51 (-0.08), MSFT: 43.87 (+0.78), BK: 39.20 (-0.21)
Mirati Therapeutics closes public offering of 2.59m common shares, including underwriters' option
M2 - Wed Feb 04, 5:24AM CST
Oncology company Mirati Therapeutics (NasdaqCM:MRTX) said on Tuesday that it has completed its public offering of 2,587,500 common stock at USD20.00 per share.
MRTX: 22.51 (-0.08)
Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire - Tue Feb 03, 3:01PM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the closing of its previously announced underwritten public offering of 2,587,500 shares of its common stock at a public offering price of $20.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 337,500 additional shares of common stock. The aggregate gross proceeds to Mirati from this offering were approximately $51.8 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati.
MRTX: 22.51 (-0.08)
InsiderInsights.com Daily Round Up 2/2/15: ALNY, MRTX, ZSAN, RLI
InsiderInsights - at Seeking Alpha - Tue Feb 03, 9:27AM CST
EGLE: 9.98 (-0.02), CKX: 15.30 (+0.34), IP: 57.31 (+0.12), ZSAN: 11.00 (-0.01), FDO: 77.86 (+0.31), SHLD: 35.70 (+2.32), VEEV: 30.12 (+0.17), DVA: 73.10 (-3.29), RLI: 49.57 (+0.47), ALNY: 95.54 (+1.67), FN: 16.94 (+0.02), FFIV: 116.64 (+1.37), MRTX: 22.51 (-0.08), MSFT: 43.87 (+0.78), MA: 87.14 (-0.38)
Mirati Therapeutics prices public offering at USD20.00 per share
M2 - Fri Jan 30, 11:14PM CST
Oncology company Mirati Therapeutics (NasdaqCM:MRTX) disclosed on Thursday that it has priced its public offering of 2,250,000 shares of its common stock at USD20.00 per share.
MRTX: 22.51 (-0.08)
Mirati Therapeutics to launch public offering of common shares
M2 - Fri Jan 30, 2:17AM CST
Oncology company Mirati Therapeutics (NasdaqCM:MRTX) disclosed on Wednesday that it plans to issue and sell shares of its common stock in a public offering.
MRTX: 22.51 (-0.08)
Mirati Therapeutics to Present at the Leerink Global Healthcare Conference
PR Newswire - Thu Jan 29, 3:01PM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at the Leerink Global Healthcare Conference on Thursday, February 12, 2015 at 8:55 a.m. Eastern Time in New York.
MRTX: 22.51 (-0.08)
Mirati Therapeutics Prices Public Offering of Common Stock
PR Newswire - Thu Jan 29, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the pricing of an underwritten public offering of 2,250,000 shares of its common stock, offered at a price to the public of $20.00 per share. The gross proceeds from this offering to Mirati are expected to be $45.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Mirati. The offering is expected to close on or about February 3, 2015, subject to customary closing conditions. In addition, Mirati has granted the underwriters a 30-day option to purchase up to an aggregate of 337,500 additional shares of common stock. All of the shares are being offered by Mirati. Mirati expects to use net proceeds of this offering for general corporate purposes, which may include clinical trial and other research and development expenses for its ongoing oncology clinical development programs, including acceleration of expenses related to clinical trial activities for the registration of MGCD265, capital expenditures, working capital and general and administrative expenses.
MRTX: 22.51 (-0.08)
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
PR Newswire - Wed Jan 28, 3:01PM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Mirati expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares are being offered by Mirati. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
MRTX: 22.51 (-0.08)
Mirati Therapeutics Doses First Patient in Phase 2 Study of Mocetinostat in Bladder Cancer Patients with Genetic Alterations of CREBBP and EP300
PR Newswire - Wed Jan 07, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient has been dosed in a Phase 2 clinical trial designed to evaluate the efficacy, safety and pharmacokinetics of mocetinostat as a treatment for a select group of patients with bladder cancer. The trial will enroll patients whose tumors have mutations or deletions of the CREBBP and/or EP300 genes.
MRTX: 22.51 (-0.08)
Mirati Therapeutics Doses First Patient in Investigator-Sponsored Phase 2 Study of Mocetinostat in Non-Hodgkin's Lymphoma
PR Newswire - Tue Jan 06, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Memorial Sloan Kettering Cancer Center in New York has dosed the first patient in an investigator-sponsored Phase 2 clinical trial of mocetinostat in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The trial will enroll patients whose tumors have mutations or deletions of the CREBBP and/or EP300 genes.
MRTX: 22.51 (-0.08)
Mirati Therapeutics Doses First Patient in Expansion Cohorts of Phase 1b Trial of MGCD265 in Genetically Selected Patients
PR Newswire - Tue Dec 23, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient with Non-Small Cell Lung Cancer (NSCLC) has been dosed in a Phase 1b clinical trial of MGCD265 in selected patients exhibiting genetic alterations of MET or Axl. In this segment of the study, one of the expansion cohorts will enroll patients with NSCLC and another will enroll patients with other solid tumors. Both cohorts will enroll only those patients that have specific MET driver mutations including MET gene point mutations, gene amplification, and MET or Axl gene rearrangements.
MRTX: 22.51 (-0.08)
Mirati Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
PR Newswire - Wed Nov 19, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 10:00 a.m. Eastern Time in New York.
MRTX: 22.51 (-0.08)
Mirati beats 3Q profit forecasts
Automated Insights - Mon Nov 10, 7:31AM CST
SAN DIEGO (AP) _ Mirati Therapeutics Inc. (MRTX) on Monday reported a third-quarter loss of $8.6 million.
MRTX: 22.51 (-0.08)
Mirati Therapeutics beats by $0.04
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:27AM CST
MRTX: 22.51 (-0.08)
Mirati Therapeutics Reports Third Quarter 2014 Financial Results and Provides Business Update
PR Newswire - Mon Nov 10, 7:00AM CST
Mirati Therapeutics, Inc. ("Mirati"
(NASDAQ: MRTX) today reported financial results for the third quarter ended September 30, 2014 and provided an update on its drug development programs.
MRTX: 22.51 (-0.08)
Michael Grey Joins Mirati Therapeutics Board of Directors
PR Newswire - Thu Nov 06, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that biotechnology industry veteran Michael Grey has joined its board of directors.
MRTX: 22.51 (-0.08)
Mirati Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference
PR Newswire - Wed Sep 10, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at BioCentury's 21st Annual NewsMakers in the Biotech Industry Conference on Friday, September 26, 2014 at 10:30 a.m. Eastern Time in New York.
MRTX: 22.51 (-0.08)
Mirati Therapeutics Initiates Phase 1 Study of MGCD516 for Non-Small Cell Lung Cancer and Other Advanced Solid Tumors
PR Newswire - Thu Sep 04, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient has been dosed in its Phase 1 clinical study of MGCD516 in the treatment of patients with advanced solid tumors, with an initial focus on non-small cell lung cancer (NSCLC). MGCD516 is a Receptor Tyrosine Kinase (RTK) inhibitor with molecular targets that act as critical genetic drivers of cancer progression.
MRTX: 22.51 (-0.08)
InsiderInsights.com Daily Round Up 2/5/15: RRC, MRTX, CG, PH
InsiderInsights - at Seeking Alpha - Fri Feb 06, 9:00AM CST
NLSN: 45.59 (+2.02), ATLS: 30.17 (+0.27), JBHT: 82.88 (+1.09), NOC: 167.14 (-0.15), PMBC: 7.20 (+0.10), AMGN: 153.48 (+0.30), MPWR: 50.32 (+0.16), SSD: 35.51 (-0.09), RRC: 50.84 (+0.07), CG: 28.18 (+0.04), WIW: 11.29 (unch), ULTI: 163.76 (+1.60), PH: 124.06 (+2.23), ONCE: 46.25 (+0.07), RWC: 5.82 (+0.06), CDNA: 6.30 (-0.14), MRTX: 22.51 (-0.08), MSFT: 43.87 (+0.78), TCON: 9.34 (-0.16), MA: 87.14 (-0.38)
5 Stocks Insiders Love Right Now: Microsoft, Alnylam and More
at The Street - Wed Feb 04, 9:02AM CST
Insiders at these companies have been scooping up shares of their own stock lately.
ALNY: 95.54 (+1.67), ALB: 54.59 (+0.63), MRTX: 22.51 (-0.08), MSFT: 43.87 (+0.78), BK: 39.20 (-0.21)
Mirati Therapeutics closes public offering of 2.59m common shares, including underwriters' option
M2 - Wed Feb 04, 5:24AM CST
Oncology company Mirati Therapeutics (NasdaqCM:MRTX) said on Tuesday that it has completed its public offering of 2,587,500 common stock at USD20.00 per share.
MRTX: 22.51 (-0.08)
Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire - Tue Feb 03, 3:01PM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the closing of its previously announced underwritten public offering of 2,587,500 shares of its common stock at a public offering price of $20.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 337,500 additional shares of common stock. The aggregate gross proceeds to Mirati from this offering were approximately $51.8 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati.
MRTX: 22.51 (-0.08)
InsiderInsights.com Daily Round Up 2/2/15: ALNY, MRTX, ZSAN, RLI
InsiderInsights - at Seeking Alpha - Tue Feb 03, 9:27AM CST
EGLE: 9.98 (-0.02), CKX: 15.30 (+0.34), IP: 57.31 (+0.12), ZSAN: 11.00 (-0.01), FDO: 77.86 (+0.31), SHLD: 35.70 (+2.32), VEEV: 30.12 (+0.17), DVA: 73.10 (-3.29), RLI: 49.57 (+0.47), ALNY: 95.54 (+1.67), FN: 16.94 (+0.02), FFIV: 116.64 (+1.37), MRTX: 22.51 (-0.08), MSFT: 43.87 (+0.78), MA: 87.14 (-0.38)
Mirati Therapeutics prices public offering at USD20.00 per share
M2 - Fri Jan 30, 11:14PM CST
Oncology company Mirati Therapeutics (NasdaqCM:MRTX) disclosed on Thursday that it has priced its public offering of 2,250,000 shares of its common stock at USD20.00 per share.
MRTX: 22.51 (-0.08)
Mirati Therapeutics to launch public offering of common shares
M2 - Fri Jan 30, 2:17AM CST
Oncology company Mirati Therapeutics (NasdaqCM:MRTX) disclosed on Wednesday that it plans to issue and sell shares of its common stock in a public offering.
MRTX: 22.51 (-0.08)
Mirati Therapeutics to Present at the Leerink Global Healthcare Conference
PR Newswire - Thu Jan 29, 3:01PM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at the Leerink Global Healthcare Conference on Thursday, February 12, 2015 at 8:55 a.m. Eastern Time in New York.
MRTX: 22.51 (-0.08)
Mirati Therapeutics Prices Public Offering of Common Stock
PR Newswire - Thu Jan 29, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the pricing of an underwritten public offering of 2,250,000 shares of its common stock, offered at a price to the public of $20.00 per share. The gross proceeds from this offering to Mirati are expected to be $45.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Mirati. The offering is expected to close on or about February 3, 2015, subject to customary closing conditions. In addition, Mirati has granted the underwriters a 30-day option to purchase up to an aggregate of 337,500 additional shares of common stock. All of the shares are being offered by Mirati. Mirati expects to use net proceeds of this offering for general corporate purposes, which may include clinical trial and other research and development expenses for its ongoing oncology clinical development programs, including acceleration of expenses related to clinical trial activities for the registration of MGCD265, capital expenditures, working capital and general and administrative expenses.
MRTX: 22.51 (-0.08)
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
PR Newswire - Wed Jan 28, 3:01PM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Mirati expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares are being offered by Mirati. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
MRTX: 22.51 (-0.08)
Mirati Therapeutics Doses First Patient in Phase 2 Study of Mocetinostat in Bladder Cancer Patients with Genetic Alterations of CREBBP and EP300
PR Newswire - Wed Jan 07, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient has been dosed in a Phase 2 clinical trial designed to evaluate the efficacy, safety and pharmacokinetics of mocetinostat as a treatment for a select group of patients with bladder cancer. The trial will enroll patients whose tumors have mutations or deletions of the CREBBP and/or EP300 genes.
MRTX: 22.51 (-0.08)
Mirati Therapeutics Doses First Patient in Investigator-Sponsored Phase 2 Study of Mocetinostat in Non-Hodgkin's Lymphoma
PR Newswire - Tue Jan 06, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Memorial Sloan Kettering Cancer Center in New York has dosed the first patient in an investigator-sponsored Phase 2 clinical trial of mocetinostat in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The trial will enroll patients whose tumors have mutations or deletions of the CREBBP and/or EP300 genes.
MRTX: 22.51 (-0.08)
Mirati Therapeutics Doses First Patient in Expansion Cohorts of Phase 1b Trial of MGCD265 in Genetically Selected Patients
PR Newswire - Tue Dec 23, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient with Non-Small Cell Lung Cancer (NSCLC) has been dosed in a Phase 1b clinical trial of MGCD265 in selected patients exhibiting genetic alterations of MET or Axl. In this segment of the study, one of the expansion cohorts will enroll patients with NSCLC and another will enroll patients with other solid tumors. Both cohorts will enroll only those patients that have specific MET driver mutations including MET gene point mutations, gene amplification, and MET or Axl gene rearrangements.
MRTX: 22.51 (-0.08)
Mirati Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
PR Newswire - Wed Nov 19, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 10:00 a.m. Eastern Time in New York.
MRTX: 22.51 (-0.08)
Mirati beats 3Q profit forecasts
Automated Insights - Mon Nov 10, 7:31AM CST
SAN DIEGO (AP) _ Mirati Therapeutics Inc. (MRTX) on Monday reported a third-quarter loss of $8.6 million.
MRTX: 22.51 (-0.08)
Mirati Therapeutics beats by $0.04
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:27AM CST
MRTX: 22.51 (-0.08)
Mirati Therapeutics Reports Third Quarter 2014 Financial Results and Provides Business Update
PR Newswire - Mon Nov 10, 7:00AM CST
Mirati Therapeutics, Inc. ("Mirati"
(NASDAQ: MRTX) today reported financial results for the third quarter ended September 30, 2014 and provided an update on its drug development programs. MRTX: 22.51 (-0.08)
Michael Grey Joins Mirati Therapeutics Board of Directors
PR Newswire - Thu Nov 06, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that biotechnology industry veteran Michael Grey has joined its board of directors.
MRTX: 22.51 (-0.08)
Mirati Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference
PR Newswire - Wed Sep 10, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present a business overview and update at BioCentury's 21st Annual NewsMakers in the Biotech Industry Conference on Friday, September 26, 2014 at 10:30 a.m. Eastern Time in New York.
MRTX: 22.51 (-0.08)
Mirati Therapeutics Initiates Phase 1 Study of MGCD516 for Non-Small Cell Lung Cancer and Other Advanced Solid Tumors
PR Newswire - Thu Sep 04, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient has been dosed in its Phase 1 clinical study of MGCD516 in the treatment of patients with advanced solid tumors, with an initial focus on non-small cell lung cancer (NSCLC). MGCD516 is a Receptor Tyrosine Kinase (RTK) inhibitor with molecular targets that act as critical genetic drivers of cancer progression.
MRTX: 22.51 (-0.08)
